Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved]
Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascula...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-04-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/7-467/v1 |
| _version_ | 1818284203645599744 |
|---|---|
| author | Daniel D. Esmaili David S. Boyer |
| author_facet | Daniel D. Esmaili David S. Boyer |
| author_sort | Daniel D. Esmaili |
| collection | DOAJ |
| description | Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) agents have a superior safety and efficacy profile for the treatment of both branch and central retinal vein occlusions. The use of wide-field fluorescein angiography has also allowed better visualization of the retinal periphery. Despite the better documentation of retinal non-perfusion, laser photocoagulation to the areas of non-perfusion does not seem to result in a reduction of macular edema or reduction in treatment burden and has been relegated to patients who develop rubeosis or neovascularization of the retina. More recently, several studies have demonstrated the use of a long-acting dexamethasone implant administered intravitreally or triamcinolone administered in the suprachoroidal space as a viable approach to treat retinal vein occlusion. |
| first_indexed | 2024-12-13T00:49:04Z |
| format | Article |
| id | doaj.art-a323b55365ff46308c4ac28aa868dd63 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-13T00:49:04Z |
| publishDate | 2018-04-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-a323b55365ff46308c4ac28aa868dd632022-12-22T00:04:57ZengF1000 Research LtdF1000Research2046-14022018-04-01710.12688/f1000research.12886.113968Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved]Daniel D. Esmaili0David S. Boyer1Retina-Vitreous Associates Medical Group, 001 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USARetina-Vitreous Associates Medical Group, 001 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USARetinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) agents have a superior safety and efficacy profile for the treatment of both branch and central retinal vein occlusions. The use of wide-field fluorescein angiography has also allowed better visualization of the retinal periphery. Despite the better documentation of retinal non-perfusion, laser photocoagulation to the areas of non-perfusion does not seem to result in a reduction of macular edema or reduction in treatment burden and has been relegated to patients who develop rubeosis or neovascularization of the retina. More recently, several studies have demonstrated the use of a long-acting dexamethasone implant administered intravitreally or triamcinolone administered in the suprachoroidal space as a viable approach to treat retinal vein occlusion.https://f1000research.com/articles/7-467/v1 |
| spellingShingle | Daniel D. Esmaili David S. Boyer Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved] F1000Research |
| title | Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved] |
| title_full | Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved] |
| title_fullStr | Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved] |
| title_full_unstemmed | Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved] |
| title_short | Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3 approved] |
| title_sort | recent advances in understanding and managing retinal vein occlusions version 1 referees 3 approved |
| url | https://f1000research.com/articles/7-467/v1 |
| work_keys_str_mv | AT danieldesmaili recentadvancesinunderstandingandmanagingretinalveinocclusionsversion1referees3approved AT davidsboyer recentadvancesinunderstandingandmanagingretinalveinocclusionsversion1referees3approved |